Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$3.47
EPS est.
$3.42
EPS surprise
+1.49%
1-day move
-0.03%
IDEXX Laboratories reported better-than-expected earnings per share, but revenue figures were not disclosed. The stock reacted slightly down by 0.03%, indicating that investors may have been looking for more comprehensive results or guidance. The lack of revenue data and management commentary could leave some investors uncertain about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.47 | $3.41 | +1.49% |
| Revenue | N/A | $1.1B | N/A |
No transcript is on record, and the analysis is based on numerical results only.
IDEXX Laboratories, Inc. is a leading provider of veterinary diagnostic products and services, primarily focused on animal health. As part of the Health Care sector, IDEXX plays a crucial role in enhancing pet care through innovative testing solutions, which are increasingly important as pet ownership rises and owners seek better health management for their animals.
Last quarter
In Q4-2025, IDEXX reported an EPS of $2.92, slightly missing the estimate of $2.93, which led to a stock decline of 4.60% the following day. The company continues to navigate a competitive landscape while focusing on innovation.
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+5.36%
Avg 1-day reaction
+6.45%
Analysts expect IDEXX to report strong earnings this quarter, with a consensus EPS of $3.41. The company has a solid track record of beating earnings estimates, which could lead to positive market reactions.
Bull case
If IDEXX exceeds expectations, it could signal strong demand for its products and services, leading to a potential stock price increase.
Bear case
Conversely, if the company fails to meet earnings expectations, it may indicate underlying issues in sales or market competition, resulting in a negative reaction from investors.
Key metrics to watch
EPS
$3.41Earnings per share is a key indicator of the company's profitability and overall financial health.
Revenue
$1.1BTotal revenue reflects the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $3.41?
A beat on EPS could reinforce investor confidence and lead to a positive stock reaction.
Q2
What insights can management provide on revenue growth and demand trends?
Understanding revenue drivers is crucial for assessing the company's future performance and market position.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate IDEXX's ability to capitalize on the growing pet care market, particularly in diagnostics.
Supporting evidence
IDEXX has historically beaten earnings estimates 75% of the time, indicating potential for positive surprises.
The recent decline in stock price following a small EPS miss may have created a buying opportunity for investors.
Options pricing suggests a significant move, indicating that traders are anticipating volatility that could favor a positive outcome.
Key risk
If revenue growth significantly outpaces expectations, it could challenge the current consensus outlook.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it follows a mixed earnings history, with recent trends showing both strong beats and misses.
Bull confirmed if
Earnings exceeding $3.41 with revenue growth indicating strong demand.
Bear confirmed if
Earnings falling below $3.35, suggesting potential weaknesses in sales.
What the market is pricing for the move.
Implied Move
±10.2%
Historical Avg
±10.1%
The options market is pricing in a significant move around the earnings announcement, suggesting that traders expect volatility.
Options are pricing ±10.7% while IDXX has averaged ±10.1% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.7%
30d HV
28.6%
Smart-money positioning from the most recent 13F filings.
Institutional
96.70%
of float
Insider
0.22%
of float
Holders
1,850
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
8,170,178 sh · $4.1B
10.37%
-2.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If IDEXX beats expectations, history suggests a potential stock increase of around 7.94%, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors assess management's commentary.
Miss
A miss could lead to a decline in stock price, with historical data suggesting an average drop of 0.73%.
The lines on the call that would change the story.
Vanguard Capital Management LLC
5,152,213 sh · $2.6B
6.54%
-0.6%
Vanguard Portfolio Management LLC
3,896,521 sh · $2.0B
4.95%
-0.4%
State Street Corporation
3,748,660 sh · $1.9B
4.76%
2.0%
Invesco Ltd.
3,611,416 sh · $1.8B
4.58%
7.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.